This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tuesday's Winners & Losers: Cell Genesys

Cell Genesys (CEGE) soared Tuesday after announcing Monday post close that it signed Japanese drug maker Takeda Pharmaceutical as a global partner for GVAX Prostate, a prostate cancer vaccine in late-stage development. Takeda will pay Cell Genesys $50 million upfront, up to $270 in milestones tied to regulatory approvals and commercialization, and also royalties on future sales. The stock added 69 cents, or 29%, to $3.04.

Akamai (AKAM) gained $2.67, or 9.5%, to $30.83 after the stock got a thumbs up from two Wall Street analysts.

An analyst at Piper Jaffray upgraded the stock to buy from neutral while a Citigroup analyst reiterated his buy rating on the belief that the company's business remains strong because of continued momentum for online video.

Then Progenics Pharmaceutical (PGNX) and Wyeth (WYE) excelled after the companies said their partnered constipation drug Relistor was approved for sale in Canada. Relistor is an injection for constipation resulting from opiate pain medications in patients with advanced illness who have tried laxatives unsuccessfully.

Progenics shares traded up 16.5% to $7.61, and Wyeth traded up 1.7% to $42.48.

Shares of Palm (PALM) were up 43 cents, or 8.6%, to $5.43 after the company said late Monday that it sold one million devices of its latest smartphone Palm Centro since it went on sale September.

Also gaining, Buffalo Wild Wings (BWLD), a Minneapolis restaurant chain, jumped 12.2% to $27.50 after Morgan Keegan bumped the stock's rating to outperform from market perform.

Shares of Kandi Technologies (KNDI), a maker of all-terrain vehicles, go-karts and other vehicles in China, zoomed ahead 15.9% to $6.48. For the full year 2007, Kandi announced income of $5 million, or 31 cents a share, vs. $1.1 million, or 10 cents a share, in 2006. Revenue more than doubled to $34.7 million.

This article was written by a staff member of TheStreet.com.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,546.09 -17.21 -0.10%
S&P 500 1,929.50 -1.17 -0.06%
NASDAQ 4,373.2640 +3.4910 0.08%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs